WT1 peptide, protein and moDC‐based vaccines have also been administered safely to patients with MDS, chronic myeloid leukaemia, non‐Hodgkin's lymphoma, multiple myeloma, paediatric leukaemias and advanced solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma.7, 10, 57, 58, 59, 60, 61, 62, 63. Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.